Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma

A randomized phase II selection design study (JCOG0904) was carried out to evaluate the more promising regimen between bortezomib (Bor) plus dexamethasone (Dex; BD) and thalidomide (Thal) plus Dex (TD) in Bor and Thal‐naïve patients with relapsed or refractory multiple myeloma (RRMM). Patients ≥20 a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Sci
Main Authors: Iida, Shinsuke, Wakabayashi, Masashi, Tsukasaki, Kunihiro, Miyamoto, Kenichi, Maruyama, Dai, Yamamoto, Kazuhito, Takatsuka, Yoshifusa, Kusumoto, Shigeru, Kuroda, Junya, Ando, Kiyoshi, Kikukawa, Yoshitaka, Masaki, Yasufumi, Kobayashi, Miki, Hanamura, Ichiro, Asai, Hiroaki, Nagai, Hirokazu, Shimada, Kazuyuki, Tsukamoto, Norifumi, Inoue, Yoshiko, Tobinai, Kensei
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5980148/
https://ncbi.nlm.nih.gov/pubmed/29478257
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13550
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados